Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tetralite influenza vaccine
- Development stage
- Unknown
- Lead developer
- LiteVax
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Tetralite is a quadrivalent influenza vaccine candidate developed by LiteVax B.V. that incorporates the company's proprietary LiteVax adjuvant. The vaccine is formulated with hemagglutinin (HA) antigens from four seasonal influenza strains: two Influenza A subtypes (H1N1 and H3N2) and two Influenza B lineages (Victoria and Yamagata). The LiteVax adjuvant is a synthetic carbohydrate-based molecule, specifically a sucrose fatty acid sulfate ester, designed to enhance the immunogenicity of the viral antigens. By stimulating both Th1 and Th2 immune pathways, the adjuvant promotes robust humoral and cellular responses, potentially allowing for dose-sparing of the viral components while maintaining high efficacy. Tetralite is intended to provide broad protection against seasonal influenza and has been evaluated in early-phase clinical trials to assess its safety and immunogenicity profile.
- Brand names
- Tetralite
- Other names
- LiteVax-adjuvanted quadrivalent influenza vaccine
02
Targets
HA (Hemagglutinin)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on Tetralite influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tetralite influenza vaccine.